Mohammad Sayed is a Co-Founder and pioneering scientist at Telos. Sayed unravelled the underlying mechanisms driving both cancer and aging, with the ultimate goal of developing targeted therapies. His research has encompassed a diverse range of subjects, including protein engineering, alternative splicing (RNA biology), and adoptive cell and gene therapies, resulting in his extensive expertise in these areas. He is the author of seven scientific publications and one US Patent.

Sayed completed Bachelors of Science in Biochemistry from Southern Methodist University. He holds a Ph.D. obtained from Dr. Shay's lab at UT Southwestern Medical Center, where he specialized in studying cancer as a disease of aging.